CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. INFORMATION THAT WAS OMITTED HAS BEEN NOTED IN THIS DOCUMENT WITH A PLACEHOLDER...License Agreement • October 9th, 2024 • Sonnet BioTherapeutics Holdings, Inc. • Pharmaceutical preparations • England and Wales
This License Agreement (hereinafter referred to as the “Agreement”) is made and effective as of the date of the last signature (the “Effective Date”), by and between SONNET BIOTHERAPEUTICS, INC. (hereinafter referred to as “SONNET”), a company organized under the laws of the state of New Jersey, USA and having its registered office at 100 Overlook Center, Suite 102, Princeton, New Jersey 08540 (which expression shall deem to mean and include its affiliates and successors), SONNET BIOTHERAPEUTICS CH SA, c/o Dr. Gael Hedou, Avenue du Temple 5, 1462 Yvonand, Switizerland, and ALKEM LABORATORIES LIMITED (hereinafter referred to as “ALKEM”), a company organized under the laws of India and having its registered office at Alkem House, Senapati Bapat Marg Road, Lower Parel (West), Mumbai 400013 India (which expression shall deem to mean and include its affiliates and successors). SONNET and ALKEM are each referred to herein as a “Party” and collectively as the “Parties”.
